N6-methyladenosine(m6A)modification is considered to be the most common eukaryotic RNA modification.Under regulation of writers,erasers and readers,m6A mediates RNA transcription,nuclear export,splicing,translation and other processes.Innate immunity is body's first line of defense against pathogen invasion,and under stimulation of pathogens and foreign bodies,it rapidly produces non-specific protective response.Recent studies have found that m6A modification plays an important role in process of innate immunity,participating in regulation of innate immunity by targeting innate immune cells,affecting immune recognition,and regulating antiviral responses.This article reviews molecular mechanism of m6A modification and its progress in innate immunity,providing new ideas for treatment strategies of related diseases based on m6A modification.

N6-methyladenosine(m6A)modification is considered to be the most common eukaryotic RNA modification.Under regulation of writers,erasers and readers,m6A mediates RNA transcription,nuclear export,splicing,translation and other processes.Innate immunity is body's first line of defense against pathogen invasion,and under stimulation of pathogens and foreign bodies,it rapidly produces non-specific protective response.Recent studies have found that m6A modification plays an important role in process of innate immunity,participating in regulation of innate immunity by targeting innate immune cells,affecting immune recognition,and regulating antiviral responses.This article reviews molecular mechanism of m6A modification and its progress in innate immunity,providing new ideas for treatment strategies of related diseases based on m6A modification.

Lung cancer is the malignancy with the highest incidence and mortality rate in China. In recent years, the popular use of low-dose computed tomography in the population has led to an increase in the detection rate of pulmonary nodules. The National Comprehensive Cancer Network (NCCN) updated and released the NCCN clinical practice guidelines in oncology for non-small cell lung cancer (version 2.2023) on February 17, 2023. This article will interpret the main updates of the new guideline and compare it with the domestic lung cancer treatment guidelines, providing new ideas for the diagnosis and treatment of lung cancer for Chinese clinicians.

Objective     To investigate the clinical characteristics and risk factors for perioperative lung surgery patients with SARS‐CoV‐2 Omicron variant infection. Methods     The clinical data of patients who underwent lung surgery at the Department of Thoracic Surgery, Renmin Hospital of Wuhan University from December 1, 2022 to January 9, 2023 were retrospectively analyzed. The patients were divided into an infection group and a non-infection group according to whether they were infected with SARS-CoV-2. And the clinical data of two groups were collected and compared. Multiple linear regression analysis was used to explore the risk factors affecting the time of hospitalization. Results     A total of 70 patients were enrolled in this study, including 36 (51.4%) males and 34 (48.6%) females at a median age of 61.0 (49.0, 66.8) years. There were 28 patients in the infection group and 42 patients in the non-infection group. The proportion of preoperative abnormal coagulation function and the risk of postoperative pulmonary infection in perioperative patients infected with SARS-CoV-2 were higher than those in the non-infection group (P<0.05). Subgroup analysis found that patients with preoperative SARS-CoV-2 infection were more likely to have pulmonary infection after surgery, but did not prolong the time of hospitalization or increase the risk of severe disease rate. The patients with postoperative SARS-CoV-2 infection had worse clinical prognosis, including longer time of hospitalization (P=0.004), higher ICU admission rate (P=0.000), higher lung infection rate (P=0.003) and respiratory failure rate (P=0.000). Multiple linear regression analysis showed that gender and extent of surgery were independent risk factors for prolonged hospitalization time. Conclusion     Preoperative infection with SARS-CoV-2 Omicron variant will increase the risk of pulmonary infection, but it will not affect the clinical prognosis. However, postoperative infection with SARS-CoV-2 Omicron variant will still prolong the time of hospitalization, increase the ICU rate, and the risk of pulmonary complications.